RASGRP4

RASGRP4 is a diacylglycerol/phorbol ester-activated guanine nucleotide exchange factor (GEF) that catalyzes GTP loading on H-Ras, N-Ras, and KRAS to drive downstream ERK, PI3Kγ/PKB, and mTOR-STAT3 signaling in myeloid and immune cells. It is recruited to the plasma membrane via its C1 domain upon DAG generation downstream of PLCβ2/β3, where it activates Ras in a cation-dependent manner to regulate mast cell maturation, prostaglandin D2 synthase expression, inflammatory cytokine production (IL-1β, TNF-α), neutrophil chemokinesis and ROS formation, and macrophage–T cell inflammatory crosstalk (PMID:11956218, PMID:22728827, PMID:22511759, PMID:39656542). Galectin-3 directly binds RASGRP4 via its N-terminal domain and inhibits Ras-GTP loading, providing a negative regulatory mechanism (PMID:18413234). RASGRP4-null mice are protected from experimental arthritis, colitis, and diabetic ischemia-reperfusion renal injury, establishing RASGRP4 as a critical mediator of mast cell- and macrophage-dependent inflammatory disease (PMID:22511759, PMID:39656542).

1. 2002 High

   Identification of RASGRP4 as a DAG/phorbol ester-responsive Ras GEF with selectivity for H-Ras and N-Ras established its core enzymatic function and placed it in the RasGRP family, revealing that mast cells and myeloid progenitors possess a dedicated DAG-to-Ras signaling module.

   Evidence Recombinant GEF assays, phorbol ester binding, PMA-induced membrane translocation, Ras-GTP pulldowns, and cytokine-independent proliferation of 32D myeloid cells in two independent studies

   PMID:11880369 PMID:11956218

   Open questions at the time

   • Crystal structure of the catalytic and C1 domains not resolved
   • Calcium/cation dependence mechanism not structurally characterized
   • Relative contributions of H-Ras vs. N-Ras activation in physiological contexts unclear
2. 2002 High

   Demonstration that RASGRP4 is required for mast cell granule maturation and controls hematopoietic PGD2 synthase expression downstream of c-Kit revealed it as a lineage-specific differentiation signal, not merely a mitogenic switch.

   Evidence Functional rescue of HMC-1 leukemia cell differentiation, GeneChip profiling, siRNA knockdown in RBL-2H3 mast cells, eicosanoid production assay

   PMID:11956218 PMID:12493770

   Open questions at the time

   • Direct biochemical link between RASGRP4-activated Ras and PGD2 synthase transcription not reconstituted
   • Intermediate transcription factors between Ras and PGD2 synthase not identified
3. 2008 Medium

   Discovery that Galectin-3 directly binds RASGRP4 and inhibits its GEF activity identified the first endogenous negative regulator of this pathway, suggesting a feedback mechanism in Ras-dependent signaling.

   Evidence Co-immunoprecipitation, Ras-GTP pulldown with Gal-3 shRNA knockdown in cancer cells

   PMID:18413234

   Open questions at the time

   • No reciprocal validation with purified recombinant proteins reported
   • Binding interface not mapped
   • Physiological relevance in mast cells or neutrophils not tested
4. 2009 Medium

   Retroviral expression of RASGRP4 caused leukemia in a bone marrow transplantation model and cooperated with AML1 mutations, establishing oncogenic potential and positioning RASGRP4 as a class I (Ras-pathway) leukemogenic factor.

   Evidence Retroviral expression-cloning screen, mouse bone marrow transplantation, factor-independence assay

   PMID:19350351

   Open questions at the time

   • Frequency of RASGRP4 gain-of-function mutations in human leukemia not established
   • Downstream effector pathway driving transformation not dissected
5. 2012 High

   Genetic epistasis in RASGRP4-null mice placed RASGRP4 between PLCβ2/β3-generated DAG and PI3Kγ-dependent PIP3/PKB signaling in GPCR-activated neutrophils, defining the full linear pathway from receptor to effector and showing essential roles in chemokinesis and ROS production.

   Evidence RASGRP4-null vs. Ras-insensitive PI3Kγ knock-in mice, PIP3 measurement, PKB phosphorylation, chemokinesis and ROS assays

   PMID:22728827

   Open questions at the time

   • Whether RASGRP4 activates H-Ras, N-Ras, or KRAS preferentially in neutrophils not determined
   • Contribution of other RasGEFs (e.g., SOS) in the same neutrophil context not quantified
6. 2012 High

   RASGRP4-null mice were protected from experimental arthritis and colitis with reduced mast cell IL-1β and TNF-α, demonstrating that RASGRP4-driven cytokine production is a critical effector mechanism in mast cell-dependent inflammatory disease.

   Evidence RASGRP4 KO mice, K/BxN serum-induced arthritis, DSS colitis model, qRT-PCR for cytokines

   PMID:22511759

   Open questions at the time

   • Whether cytokine regulation is direct via Ras-ERK or indirect via other pathways not resolved
   • Human genetic evidence linking RASGRP4 variants to arthritis or colitis absent
7. 2016 Medium

   Extending expression beyond mast cells, RASGRP4 was found in splenic CD117+ dendritic cells and shown to be required for optimal NK cell IFN-γ induction, broadening its innate immune role.

   Evidence RASGRP4-null mice, splenic DC isolation, NK cell co-culture, IFN-γ ELISA/flow cytometry

   PMID:26982501

   Open questions at the time

   • Signaling pathway downstream of RASGRP4 in DCs not characterized
   • Whether the NK cell defect is cell-intrinsic or driven entirely by DC dysfunction not fully separated
8. 2024 Medium

   RASGRP4 was shown to promote M1 macrophage polarization and Th17 differentiation via IL-17 signaling, with RASGRP4-KO mice protected from diabetic ischemia-reperfusion renal injury, establishing a macrophage–T cell inflammatory axis dependent on RASGRP4.

   Evidence RASGRP4-KO mice, renal IRI model, flow cytometry, in vitro high glucose/hypoxia-reoxygenation, IL-17 pathway protein analysis

   PMID:39656542

   Open questions at the time

   • Whether RASGRP4 acts cell-autonomously in macrophages or T cells not fully distinguished
   • Apparent contradiction with M2-promoting role in tumor macrophages (PMID:40515877) not reconciled
9. 2025 Medium

   The CXCL8-CXCR2 axis was shown to upregulate RASGRP4 via PLCβ2, and RASGRP4 in turn promoted M2 macrophage polarization through mTOR-STAT3, connecting chemokine receptor signaling to RASGRP4-dependent immunosuppressive macrophage programming in cancer.

   Evidence CXCR2 inhibition/siRNA, PLCβ2 siRNA, RASGRP4 KD/OE in THP-1 cells, xenograft model, mTOR-STAT3 pathway analysis

   PMID:40515877

   Open questions at the time

   • Ras isoform activated by RASGRP4 in this macrophage context not specified
   • Context-dependent M1 vs. M2 polarization outcome not mechanistically explained
10. 2026 Medium

    RASGRP4 cooperates with SOS to maintain high basal KRAS-GTP levels in adrenocortical carcinoma cells, and its CRISPR depletion reduces tumor growth, establishing RASGRP4 as a functionally relevant KRAS co-activator in solid tumors.

    Evidence ODE modeling, PCR panel, CRISPR KO of RASGRP4, nude mouse xenograft tumor growth

    PMID:41792200

    Open questions at the time

    • Whether RASGRP4 directly activates KRAS (versus H-Ras/N-Ras) biochemically not confirmed
    • Generalizability to other KRAS-driven cancers not tested

• Key unresolved questions include the structural basis for RASGRP4's cation-dependent GEF activity, the molecular determinants governing context-dependent M1 versus M2 macrophage polarization, whether RASGRP4 gain-of-function mutations contribute to human leukemia or inflammatory disease, and how Galectin-3 inhibition is regulated in physiological settings.
• No crystal or cryo-EM structure of RASGRP4 available
• Context-dependent macrophage polarization outcome (M1 vs. M2) not mechanistically resolved
• Human genetic evidence for RASGRP4 in disease is lacking